NeoDynamics at largest German breast cancer congress
The MedTech company NeoDynamics AB (publ) showcased its novel biopsy system NeoNavia at the 41st Congress of the German Society of Senology, the most important breast cancer congress in the German speaking area when it resumed after a break during the pandemic. Professor Marc Thill presented an update on the PULSE study, involving NeoNavia at the meeting.
Apart from Professor Marc Thill’s presentation, NeoNavia was also referred to as a new method for axillary management by PD Dr Ines Gruber from the University Hospital Tübingen. NeoDynamics also participated in the conference, that ended this weekend, with a sales booth.
“It is great that the most important breast cancer congress in Germany is back as a live event. We could showcase NeoNavia hands-on at our booth and pick up new German and Swiss leads that we will follow up on. We strengthened relationships with key opinion leaders and are especially excited that NeoNavia found its way into several presentations at the educational sessions. We’re gaining traction,” says Renate Reiss, country manager for the DACH region.
For further information, please contact:
CEO Anna Eriksrud, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com
CFO Aaron Wong, phone +46 735 972 011 or e-mail [email protected]
About NeoDynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia has received CE approval and is bing marketed in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients. NeoDynamic´s share is listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB, e-mail address: [email protected] and telephone number +46 8 121 576 90.
